Recent Developments in Starpharma Holdings Limited
Starpharma Holdings Limited (SPL.AX) finished the trading day on Friday, 23 November 2026, with its shares down 2.08 % to a closing price of AUD 0.46. The company’s market capitalisation stands at AUD 155.6 million, with an average daily turnover of approximately AUD 1.6 million over the past 24 hours. Over the last month, the stock has declined 42.33 %, reflecting market volatility and the company’s ongoing strategic initiatives.
Core Business Progress
Starpharma has announced significant progress in its lead radiopharmaceutical program. The company is moving its DEP® HER2‑Lu asset toward a first‑in‑human Phase 1 study in the Netherlands, marking a critical milestone in the development of targeted oncology therapies. In parallel, Starpharma has secured a partnership with Genentech and received a milestone payment from Radiopharm Theranostics. The payment could unlock additional funding if the option is exercised, providing a potential boost to the company’s research pipeline.
A further development is Starpharma’s increased equity stake in Petalion Therapeutics. The company has moved to majority ownership, positioning itself to steer the development of the FAP‑targeted DEP® oncology program. This strategic move aligns with Starpharma’s focus on expanding its oncology portfolio and strengthening its position in the biopharmaceutical market.
Capital Structure and Governance
Starpharma recently completed a fully underwritten entitlement offer valued at approximately AUD 32 million. The injection of cash has strengthened the company’s balance sheet, supporting ongoing research and development activities. Governance changes were also announced: long‑standing chair Rob Thomas retired, and Dr Russell Basser was appointed chair, with Dr David McIntyre assuming the role of deputy chair. These appointments signal a strategic emphasis on targeted oncology and international expansion.
Stock Performance Context
The company’s 200‑day simple moving average is currently at AUD 0.63, below the recent closing price, indicating a short‑term bullish bias that may reverse if the stock fails to maintain upward momentum. The highest price of the past 52 weeks was AUD 0.88 (recorded on 30 September 2026), while the 52‑week low was AUD 0.30 (recorded on 28 October 2025). This volatility underscores the need for investors to monitor both market sentiment and the company’s clinical milestones.
Comparative Performance of Peer Shares
| Stock | 24‑Hour Movement | Current Price (AUD) | Market Cap (AUD mn) | P/E Ratio |
|---|---|---|---|---|
| Fiducian (FID.AX) | +1.22 % | 8.40 | 175.6 | 19.38 |
| Tribune (TBR.AX) | +0.39 % | 5.03 | 179.8 | 3.51 |
| Global Lithium (GL1.AX) | –1.57 % | 0.91 | 179.1 | – |
| Stealth (SGI.AX) | +1.24 % | 1.22 | 180.8 | 30.43 |
| Actinogen Medical (ACW.AX) | –2.08 % | 0.05 | 186.0 | – |
While Starpharma’s shares have experienced a notable decline, peers such as Fiducian and Stealth have shown modest gains, reflecting sector‑specific dynamics and investor confidence in different business models.
Governance Highlights of Related Companies
Global Lithium (GL1.AX) is preparing for its first annual general meeting on 24 November 2026, where shareholders will consider the annual financial report, remuneration report, auditor appointment, and a special resolution to increase the company’s equity‑issue capacity under Listing Rule 7.1A.
Actinogen Medical (ACW.AX) held its 2026 annual shareholders’ meeting on 18 November 2026, focusing on director‑election motions and the approval of a 10 % placement facility. The meeting was conducted virtually, in compliance with ASX requirements.
Company Overview
Starpharma Holdings Limited is a biopharmaceutical company specializing in dendrimer‑based products across multiple therapeutic areas, with a particular emphasis on oncology and infectious diseases. The company’s mission is to address unmet patient needs through innovative research and commercialization of its product portfolio. Investors may find additional information on Starpharma’s initiatives and offerings on its website at www.starpharma.com , and the company remains listed on the ASX All Markets.
